Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 30 versus OCUSULF 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 30 versus OCUSULF 10.
BLEPH-30 vs OCUSULF-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLEPH-30 is a topical formulation containing 30% sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, interfering with folic acid synthesis and exerting bacteriostatic activity against susceptible organisms.
Sulfacetamide sodium is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and exerting bacteriostatic effects.
One drop to the affected eye(s) every 12 hours. Not to exceed 2 drops per eye per day.
Instill 1 drop into the affected eye(s) every 4 hours while awake.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours in adults with normal renal function; clinically, dosing intervals may need adjustment in renal impairment.
1.5–2.5 hours (terminal) in adults; prolonged to 3–5 hours in renal impairment (CrCl <30 mL/min).
Primarily renal excretion of unchanged drug, accounting for approximately 90% of elimination; minor biliary/fecal route (<10%).
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic